176 results on '"Rubinstein, Jeremy"'
Search Results
2. Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis
3. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
4. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults
5. Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults
6. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant
7. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
8. Blinatumomab as maintenance therapy for pediatric acute B-lymphoblastic leukemia in the setting of asparaginase-associated pancreatitis
9. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted
10. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients
11. Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation
12. Clinical Response to Virus-Specific T-Cells Is Not Impacted By T-Cell Co-Stimulation Inhibition
13. Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease
14. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL
15. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
16. P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE
17. Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience
18. Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel
19. Use of gemcitabine, oxaliplatin, and anti‐CD20 therapy in children and adolescents with non‐Hodgkin lymphoma unfit for intensive therapy
20. Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders
21. An exceptional case of durable remission achieved with reinfusion of CD19-directed CAR-T despite failure to induce B-cell aplasia and review of institutional experience with reinfusion of tisagenlecleucel
22. Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric PTLD collaborative
23. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
24. Pediatric EBV-negative monomorphic post–solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.
25. Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders.
26. Acute myeloid leukemia in SRP54‐mutated congenital neutropenia
27. Availability of Donor Derived Patient Specific Virus-Specific T-Cells (VSTs) Is Not Associated with Differences in Outcomes As Compared to Frontline Administration of Third Party Vsts for the Management of Viral Infections after Pediatric Hematopoietic Stem Cell Transplant
28. Significant Therapy Associated Toxicity Seen in Two Pediatric Survivors of Medulloblastoma Treated with Tisagenlecleucel for Relapsed Secondary B-Cell Acute Lymphoblastic Leukemia
29. Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients
30. Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
31. Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
32. Outcome of Post Solid Organ Transplant Burkitt Lymphoma (PSOT-BL): A Report from the Pediatric PTLD Collaborative (PPC)
33. Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia
34. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effective
35. Scheduled Donor-Derived Viral Specific T-Cells for Prophylaxis Against Double Stranded DNA Viral Infection after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation
36. T Cell Co-Stimulatory Blockade By CTLA4-Ig Does Not Appear to Impact the Clinical Efficacy of Viral Specific T Cell Therapy in Pediatric Patients after HSCT
37. Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis
38. Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy
39. Allogeneic Viral Specific T Cells Are Safe and Can be Efficient in the Treatment of Infections in Solid Organ Transplant Recipients
40. Characterization of Viral Epitopes and the HLA Restriction That Govern Anti-Adenoviral Response to Viral Specific T-Lymphocyte Therapy in a Pediatric Cohort
41. Pre-Transplant Baseline Platelet Count and the Number of Peri-HSCT Transfusions Are Associated with an Increased Disease-Free Mortality Rate in a Large Pediatric Cohort
42. Chimeric antigen receptor T‐cell therapy in patients with neurologic comorbidities
43. A case of submandibular desmoplastic small round cell tumor: Diagnostic and management approaches to an atypical presentation of a rare tumor
44. EBV‐directed viral‐specific T‐lymphocyte therapy for the treatment of EBV‐driven lymphoma in two patients with primary immunodeficiency and DNA repair defects
45. 477 - Availability of Donor Derived Patient Specific Virus-Specific T-Cells (VSTs) Is Not Associated with Differences in Outcomes As Compared to Frontline Administration of Third Party Vsts for the Management of Viral Infections after Pediatric Hematopoietic Stem Cell Transplant
46. 257 - Significant Therapy Associated Toxicity Seen in Two Pediatric Survivors of Medulloblastoma Treated with Tisagenlecleucel for Relapsed Secondary B-Cell Acute Lymphoblastic Leukemia
47. CD40 Ligand Levels in Pediatric Cohorts Correlate with Baseline Platelet Count and Transplant-Associated Mortality but Not with Endothelial Injury
48. Surgical and anesthetic management for hepatectomy in two pediatric patients with trisomy 18, pulmonary hypertension, and hepatoblastoma
49. Expanding the pediatric oncology medical home: Successful utilization of a medical‐legal partnership at a pediatric oncology referral center
50. Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.